Cargando…

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin

Detalles Bibliográficos
Autores principales:	Mankhatitham, W, Lueangniyomkul, A, Manosuthi, W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113098/ http://dx.doi.org/10.1186/1758-2652-13-S4-P90

Ejemplares similares

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
por: Aragão, F, et al.
Publicado: (2010)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2012)

Clinical and paraclinical aspects of HIV infected patients with first-line antiretroviral regimens
por: Bîstrițchi, Ina, et al.
Publicado: (2013)

Antiretroviral regimen complexity as a predictor of adherence
por: Boyle, C, et al.
Publicado: (2010)

No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects
por: Vourvahis, M, et al.
Publicado: (2010)

Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen
por: Wikman, P, et al.
Publicado: (2010)

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens
por: Wiesmann, Frank, et al.
Publicado: (2014)

Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine
por: Siripassorn, Krittaecho, et al.
Publicado: (2013)

Duration of antiretroviral regimens in treatment-experienced patients in clinical practice
por: Vilaplana, Vicente Escudero, et al.
Publicado: (2010)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

Treatment outcomes in patients receiving combination antiretroviral therapy
por: Agu, Kenneth, et al.
Publicado: (2010)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Clinical and immulogical outcomes among adult patients receiving Antiretroviral Therapy (ART) at an HIV/AIDS program in Uganda
por: Muhumuza, Simon, et al.
Publicado: (2010)

Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile
por: Mori, J, et al.
Publicado: (2010)

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
por: Gupta, Shaili, et al.
Publicado: (2014)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2009)

Multiple dosage forms of the NNRTI microbicide dapivirine: product development and evaluation
por: Romano, Joseph
Publicado: (2006)

HIV-1 evolution and drug resistance among patients receiving antiretroviral therapy in San Mateo county, California, 1997-2006
por: Dalai, Sudeb, et al.
Publicado: (2010)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
por: Bunupuradah, Torsak, et al.
Publicado: (2011)

HIV drug resistance profile of HIV-1 CRF 01_AE protease and integrase coding regions in HIV infected Cambodian patients failing LPV-based 2(nd) line antiretroviral regimen
por: Nouhin, Janin, et al.
Publicado: (2011)

Non hepatitis jaundice - adverse reaction to rifampicin
por: Laza, Ruxandra, et al.
Publicado: (2014)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen
por: Tsai, Hung-Chin, et al.
Publicado: (2022)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole
por: Manosuthi, Weerawat, et al.
Publicado: (2007)

Efficiency of rifampicin–miconazole-impregnated catheters in the femoral venous site
por: Lorente, L, et al.
Publicado: (2009)

Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya
por: Beck, Ingrid A., et al.
Publicado: (2020)

Development of a single-tube, low-cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co-infected patients
por: Fox, D, et al.
Publicado: (2010)

Rifampicin and colistin association in the treatment of severe multiresistant Acinetobacter baumannii infections
por: Charra, B, et al.
Publicado: (2008)

Adherence to HIV treatment guidelines for initiation of antiretroviral therapy in Australia
por: Bloch, M, et al.
Publicado: (2010)

Screening of some savannah plants for antiretroviral (ANTI-HIV) activity
por: Mukhtar, MD, et al.
Publicado: (2009)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co–therapy
por: Li, Feng, et al.
Publicado: (2013)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment
por: Sinha, Sanjeev, et al.
Publicado: (2011)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study
por: Manosuthi, Weerawat, et al.
Publicado: (2005)

Immune impairment and adaptive response in relation to antiretroviral therapy of HIV-infection
por: Kaminskiy, GD, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_apaodb0kkie7rmtemi3bd4t9u9